News · Heart & Metabolic
Left-side breast radiotherapy raised heart risk only in women who already had three risk factors
Radiotherapy to the left breast puts the heart in the field, and modern technique was supposed to have solved it. Across 23,305 women, the residual harm turned out to sit almost entirely in one group.
- Left-side treatment carried about 11% more heart disease than right-side overall.
- Women with none or few heart risk factors showed no measurable difference.
- Women with three or more carried about 37% more.
- The comparison is left against right, so the cancer itself cancels out.
- 23,305 women, average age 52 when treated.
The heart sits a little to the left. That anatomical detail has shadowed breast cancer treatment for forty years, because radiotherapy aimed at a left breast passes through territory a right-sided treatment does not.
The consequence showed up decades later as heart disease in women cured of their cancer, and it drove a long engineering effort: treating patients on a held breath so the chest wall lifts away from the heart, shaping the beam more tightly, planning in three dimensions. Cardiac doses today are a small fraction of what they were.
The question is whether anything is left. Writing in the journal JAMA Network Open, researchers compared the two sides directly. Of 23 305 patients, about half received left-sided treatment and half right-sided, and previously nobody had asked whether the residual harm falls evenly across them.
Why left against right is a good comparison
Almost every study of treatment harm struggles with the same problem: the people who get the treatment differ from the people who do not.
This design sidesteps it. Everyone has breast cancer, everyone had radiotherapy, and which breast the tumor appeared in is not chosen by the patient, the surgeon or the insurer. It is as close to random assignment as observational oncology gets.
So a difference between the two groups is about where the beam went, not about who received it.
The overall figure, and why it understates things
Left-sided treatment carried about 11% more ischemic heart disease across the whole cohort, a difference small enough that its range only just clears no effect at all.
Taken alone, that reads like a reassuring result: forty years of engineering has ground a serious hazard down to a modest one.
Then the cohort splits by baseline cardiovascular risk, and the average turns out to be hiding two different populations.
Where the harm actually sits
Among patients with 0 to 2 cardiovascular risk factors, no measurable difference emerged between left and right at all.
Among women with three, left-sided treatment carried around 37% more heart disease.
The overall 11% is therefore not a small harm spread thinly across everyone. It is a substantial harm concentrated in a minority, diluted by a majority in whom nothing measurable happened.
That distinction is the difference between a fact and a usable fact. An average applied to every patient tells a clinic nothing about which patient to worry about.
The plausible reason
Radiation injures blood vessels, including the small coronary arteries at the front of the heart that a left-sided field is most likely to catch.
A woman with healthy arteries has margin to absorb that. A woman whose arteries are already narrowing under the pressure of diabetes, hypertension, smoking and cholesterol has less. The same dose lands on a system with no reserve.
This is the ordinary pattern of interacting risks rather than anything exotic, and it is why identifying who carries the burden matters more than knowing the average.
What the study cannot rule out
Radiotherapy heart disease is famously slow. The classic studies found excess cardiac deaths accumulating for twenty and thirty years after treatment, and a cohort with a shorter horizon will catch the early part of that curve only.
Women who look unaffected here may not be unaffected at seventy. Risk factors also accumulate: a woman treated with one at 52 may have three by 65, at which point the group she belongs to has changed and the exposure already happened.
The study reports what was recorded at treatment, which is the right thing to report and not the whole life.
What it should change
Not whether women have radiotherapy. Breast cancer is the second most common cancer in women, radiotherapy after surgery substantially reduces recurrence and death from it, and the benefit dwarfs the effect described here.
What it should change is where the effort goes. Heart-sparing technique, cardiology input, and treating blood pressure and cholesterol before radiotherapy starts are finite resources, and this study says which patients they buy the most for.
For a woman with a left-sided tumor and three cardiovascular risk factors, the finding is not a reason to decline treatment. It is a reason to ask what her center is doing about her heart.
People also ask
What did the study find?
Left-sided radiotherapy was associated with higher ischemic heart disease risk overall (subdistribution hazard ratio 1.11; 95% CI 1.01-1.22; P = .04). No significant difference appeared among patients with 0 to 2 cardiovascular risk factors, while among those with 3 risk factors the adjusted sHR was 1.37 (95% CI 1.10-1.71; Gray test P = .004).
Why compare left against right?
Because the heart sits slightly left of center, so left-sided treatment exposes it and right-sided treatment largely does not. Both groups have breast cancer, both had radiotherapy, and which breast was affected is not something patients or doctors choose. It is close to a natural experiment.
Hasn't modern radiotherapy fixed this?
Largely. Techniques such as treating on a held breath move the heart away from the field, and cardiac doses today are a fraction of what they were. This study says a residue remains, and locates it.
Which risk factors count?
The usual cardiovascular ones: high blood pressure, diabetes, high cholesterol, smoking, obesity. The study grouped patients by how many they carried at the time of treatment.
Does this mean low-risk women can stop worrying?
It means no measurable excess appeared for them in this cohort over this follow-up. Absence of a detectable difference is not proof of no difference, and radiotherapy effects on the heart can take decades to surface.
What would a clinic do differently?
Mainly triage. If the residual harm concentrates in women with several risk factors, then heart-sparing technique, cardiology input and risk factor treatment matter most for them, rather than being spread evenly.
Should anyone refuse radiotherapy over this?
No. Radiotherapy after breast cancer surgery substantially reduces recurrence and death from the cancer, and that benefit is far larger than the effect described here. Treatment decisions belong with an oncologist. This is general information rather than medical advice.